



7<sup>th</sup>

Tinos Island  
GREECE

# International Lung Cancer Seminar

4 - 6 September 2020

Cultural Foundation of Tinos

[www.7thlungcancerseminar2020.gr](http://www.7thlungcancerseminar2020.gr)

# PRELIMINARY PROGRAM

Friday September 4, 2020

13.30-14.30 *Registration opens*

14.30-15.00 Lecture I

Chairpersons: V. Iordanoglou, C. Marinou

Smoking and lung cancer epidemiology  
K. Pouloupoulos

15.00-15.30 Lecture II

Chairpersons: V. Polychronopoulos, I. Davlopoulos

E-cigarette and heated tobacco : A new old story  
D. Kyroussis

15.30-16.00 Lecture III

Chairpersons: I. Andreou, I. Kostara

Imaging evaluation of response in NSCLC  
Th. Pipikos

16.00-16.30 Lecture IV

Chairpersons: L. Zellos, M. Doris, I. Titopoulos

Minimal thoracic surgery-maximum efficacy. What new in 2020  
C. Iliadis

**16.30-17.00 Coffee break**

17.00-18.00 Round Table I: THYMOMA

Chairpersons: A. Petounis, D. Malios, P. Skarlos

Histological classification and prognosis  
S. Papadopoulos

Surgery  
L. Toufexian

Radiotherapy  
I. Georgakopoulos

Novel treatments  
E. Res



**18.00-18.30 Satellite Lecture I**

Chairpersons: P. Kosmidis, A. Gaga

**kras G12G: Identifying new driving mutation in NSCLC**

I. Boukovinas

**18.30-19.00 Lecture V**

Chairpersons: C. Christodoulou, A. Kotsakis

**Mesothelioma: Immunotherapy. When? Any progress?**

S. Demiri

**19.00-19.30 Satellite Lecture II**

Chairpersons: P. Kosmidis, D. Stamatopoulos

**Thromboembolic events in NSCLC. Is there a real threat?**

I. Boukovinas

**19.30-20.00 Workshop I: Artificial Intelligence: here to stay?**

Chairpersons: A. Nikolaidi, N. Kentepozidis, N. Desses

- **Genomics: Predict treatment?: G. Lypas**
- **Radiomics: Replace biopsy?: N. Papanikolaou**

**20.00-20.30 Controversies I: EARLY LUNG CANCER IN SPECIFIC GROUPS**

Chairpersons: E. Samantas, M. Piperi, F. Stavridi

**Surgery: N. Baltagiannis**

**Radiotherapy: S. Kosmidis**

**20.30-21.00 Opening Ceremony**

**Welcome addresses**

**I. Boukovinas** (President of HESMO)

**G. Fountzilas** (President of HeCOG)

**P. Kosmidis** (President of the Seminar)

**C. Iliadis** (President of the Seminar)

**HONORARY LECTURE**

**21.00**

**Welcome Reception**

# Saturday September 5, 2020

## 09.00-09.30 Lecture VII

Chairpersons: D. Pectasides, K. Ploiarchopoulou, A. Koumarianou

Tumor heterogeneity and resistance to treatment  
S. Lambropoulos

## 09.30 – 10.30 Round Table II: RESISTANCE TO IMMUNE CHECK POINT INHIBITORS

Chairpersons: E. Samantas, C. Marinou, N. Mitsimponas

Intrinsic to relation to driver mutation  
A. Laskarakis

Intrinsic in relation to TMB  
A. Stribakos

Acquired resistance  
E. Saloustros

## 10.30 – 11.30 Round Table III: IMMUNOTHERAPY: NEW AVENUES

Chairpersons: G. Fountzilias, S. Murray, C. Margari

Adjuvant: H. Linardou

Neoadjuvant: I. Mountzios

Maintenance: I. Athanasiadis

## 11.30-12.00 Satellite Lecture III

SPONSORED BY BRISTOL MYERS SQUIBB

Chairpersons: A. Psyrri, C. Andreadis

The Dual Inhibition of Check point Inhibitors in 1<sup>st</sup> line NSCLC treatment  
H. Linardou

## 12.00-12.30 *Coffee Break*

## 12.30-13.00 Lecture VIII

Chairpersons: F. Matsouka, V. Polychronopoulos

Immunotherapy in small cell lung cancer. Any hope?  
A. Nikolaidi

## 13.00-13.30 Controversies II: CAN WE TAILOR THE DURATION OF IMMUNOTHERAPY?

Chairpersons: A. Psyrri, C. Bakogiannis, D. Tryfonopoulos

Up to 2 years: G. Lainakis

Indefinitely: A. Kotsakis

13.30-14.30 Round Table III: 2<sup>nd</sup> LINE TREATMENT FOLLOWING IMMUNOTHERAPY  
Chairpersons: V. Georgoulas, A. Laskarakis, K. Ploiarchopoulou

During relapse: Z. Saridaki

Following 2 years of treatment and relapse: V. Barbounis

Hyperprogressive disease: N. Kentepozidis

**14.30-15.30 Light Lunch**

15.30-16.00 Workshop II: METASTASIS  
Chairpersons: P. Papakostas, D. Tryfonopoulos, S. Demiri

- Oligometastasis. What to do?: H. Galani
- Oligoprogession. What to do?: C. Panopoulos

16.00-16.30 Lecture IX  
Chairpersons: L. Florentin, S. Murray, S. Livanos

Genotyping: From academic research to clinical practice: G. Nasioulas

16.30-17.30 Round Table IV: FIRST LINE FOR ONCOGENE ADDICTED LUNG CANCER  
Chairpersons: G. Koumakis, V. Ramfidis, C. Antonopoulos

Key factors that determine the selection of first line EGFR TKI: F. Stavridi

Key factors that determine the selection of first line ALK inhibitors: C. Andreadis

17.30-18.00 Satellite Lecture IV SPONSORED BY NOVARTIS HELLAS  
Chairpersons: D. Bafaloukos, G. Rigakos, J. Mountzios

Non small cell lung cancer: The importance of BRAF mutation: M. Tsiatas

**18.00-18.30 Coffee Break**

18.30-19.00 Satellite Lectures V SPONSORED BY ASTRA ZENECA  
Chairpersons: P. Papakostas, A. Petounis

Therapeutic approaches beyond chemotherapy in the adjuvant setting of NSCL:  
A. Koumariou

**New perspectives and challenges in the treatment of SCLC: Th. Tegos**

**19.00-19.30 Workshop III: CARCINOID LUNG TUMORS**

**Chairpersons: C. Iliadis, N. Chatzinikolaou, E. Res**

- **Surgery: state of the art: L. Zellos**
- **Targeted treatment: A. Koumarianou**

**19.30-20.00 Satellite Lecture VI**

**SPONSORED BY PFIZER HELLAS**

**Chairpersons: H. Linardou, A. Lalousis, S. Saridaki**

**Developing next generation inhibitors in the management of ALK+ NSCLC;  
focusing on 3rd generation: A. Christopoulou**

## Sunday September 6, 2020

10.00-11.00 Round Table V: COMBINED TREATMENT IN STAGE III NSCLC  
Chairpersons: E. Zachariadis, C. Tsigaridas, I. Georgakopoulos

Concurrent chemoradiotherapy: V. Rapti

Concurrent Immunoradiotherapy: M. Theochari

Radiation combined with targeted treatments: M. Piperi

11.00-11.30 Workshop IV: Brain metastasis  
Chairpersons: F. Matsouka, N. Mitsimponas, N. Desses

- Brain metastasis: are all the same?: G. Rigakos
- Radiotherapy: when? How?: P. Skarlos

11.30-13.00 Round Table VI: ASCO 2020  
Chairpersons: C. Bakogiannis, H. Goniotaki, A. Lalouis

Small cell lung cancer: V. Ramfidis

NSCLC: Chemotherapy: TBA

NSCLC: Targeted therapy: C. Margari

NSCLC: Immunotherapy: P. Papadopoulos

13.00-13.30 **Closing Remarks**